Increased HIV-1 Immunogenicity of Replication Competent NYVAC
Background: The human RV144 efficacy trial revealed a 31% efficacy rate against acquisition of HIV infection using the ALVACvcp1521/ AIDSVAX gp120 B/E prime boost regimen. In addition to a modest efficacy rate, the duration of protection was relatively short-lived, suggesting that both vaccine compo...
Gespeichert in:
Veröffentlicht in: | AIDS research and human retroviruses 2013-11, Vol.29 (11), p.A-160 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: The human RV144 efficacy trial revealed a 31% efficacy rate against acquisition of HIV infection using the ALVACvcp1521/ AIDSVAX gp120 B/E prime boost regimen. In addition to a modest efficacy rate, the duration of protection was relatively short-lived, suggesting that both vaccine components must be improved. The Copenhagen vaccinia derived replication deficient NYVAC has been shown to be highly immunogenic in combination with DNA priming in both non-human primates (NHPs) and human clinical trials. |
---|---|
ISSN: | 0889-2229 |